nach oben

Internal and Emergency Medicine

Erschienen in:

09.05.2020 | COVID-19 | CE-Systematic reviews and meta-analysis Zur Zeit gratis

Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?

verfasst von: Konstantinos Farsalinos, Anastasia Barbouni, Raymond Niaura

Erschienen in: Internal and Emergency Medicine | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

The effects of smoking on Corona Virus Disease 2019 (COVID-19) are currently unknown. The purpose of this study was to systematically examine the prevalence of current smoking among hospitalized patients with COVID-19 in China, considering the high-population smoking prevalence in China (26.6%). A systematic review of the literature (PubMed) was performed on April 1. Thirteen studies examining the clinical characteristics of hospitalized COVID-19 patients in China and presenting data on the smoking status were found. The pooled prevalence of current smoking from all studies was calculated by random-effect meta-analysis. To address the possibility that some smokers had quit shortly before hospitalization and were classified as former smokers on admission to the hospital, we performed a secondary analysis in which all former smokers were classified as current smokers. A total of 5960 patients were included in the studies identified. The current smoking prevalence ranged from 1.4% (95% CI 0.0–3.4%) to 12.6% (95% CI 10.6–14.6%). An unusually low prevalence of current smoking was observed from the pooled analysis (6.5%, 95% CI 4.9–8.2%) as compared to population smoking prevalence in China. The secondary analysis, classifying former smokers as current smokers, found a pooled estimate of 7.3% (95% CI 5.7–8.9%). In conclusion, an unexpectedly low prevalence of current smoking was observed among patients with COVID-19 in China, which was approximately 1/4th the population smoking prevalence. Although the generalized advice to quit smoking as a measure to reduce health risk remains valid, the findings, together with the well-established immunomodulatory effects of nicotine, suggest that pharmaceutical nicotine should be considered as a potential treatment option in COVID-19.

Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46(4):586–590. https://doi.org/10.1007/s00134-020-05985-9CrossRefPubMedPubMedCentral

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD (2020) Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMsr2005760CrossRefPubMedPubMedCentral

Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X (2018) Nicotine and the renin–angiotensin system. Am J Physiol Regul Integr Comp Physiol 315(5):R895–R906. https://doi.org/10.1152/ajpregu.00099.2018CrossRefPubMedPubMedCentral

Yue X, Basting TM, Flanagan TW, Xu J, Lobell TD, Gilpin NW, Gardner JD, Lazartigues E (2018) Nicotine downregulates the compensatory angiotensin-converting enzyme 2/angiotensin type 2 receptor of the renin–angiotensin system. Ann Am Thorac Soc 15(Suppl 2):S126–S127. https://doi.org/10.1513/AnnalsATS.201706-464MGCrossRefPubMedCentral

Cai G (2020) Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov. https://doi.org/10.20944/preprints202002.0051.v3

Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, Dorscheid DR, Sin DD (2020) ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. medRxiv 2020.03.18.20038455. https://doi.org/10.1101/2020.03.18.20038455(prepublication)

Blake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS (2020) Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). J Clin Med 9(3):841. https://doi.org/10.3390/jcm9030841CrossRef

Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11:875–879CrossRefPubMedPubMedCentral

Dijkman R, Jebbink MF, Deijs M, Milewska A, Pyrc K, Buelow E, van der Bijl A, van der Hoek L (2012) Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63. J Gen Virol 93:1924–1929CrossRefPubMed

10.

Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436(7047):112–116CrossRefPubMedPubMedCentral

11.

Gurwitz D (2020) Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. https://doi.org/10.1002/ddr.21656CrossRefPubMedPubMedCentral

12.

World Health Organization (WHO). Global Adult Tobacco Survey (GATS). Fact sheet China 2018. https://www.who.int/docs/default-source/wpro---documents/countries/china/2018-gats-china-factsheet-cn-en.pdf?sfvrsn=3f4e2da9_2. Accessed 30 Mar 2020

13.

Cai H (2020) Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. https://doi.org/10.1016/S2213-2600(20)30117-XCrossRefPubMedPubMedCentral

14.

Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX, China Medical Treatment Expert Group for Covid-19 (2020) Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. https://doi.org/10.1183/13993003.00547-2020CrossRefPubMedPubMedCentral

15.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 (2020) Clinical characteristics of coronavirus disease, 2019 in China. N Engl J Med. https://doi.org/10.1056/NEJMoa2002032CrossRefPubMedPubMedCentral

16.

Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, Jia H, Hu J, Gao J, Zhang Y, Zhang X, Yu G, Wang X, Gu J, Ye C, Jin C, Lu Y, Yu X, Yu X, Ren Y, Qiu Y, Li L, Sheng J, Yang Y (2020) Analysis of epidemiological and clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa242CrossRefPubMedPubMedCentral

17.

Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, Hao SR, Jia HY, Cai H, Zhang XL, Yu GD, Xu KJ, Wang XY, Gu JQ, Zhang SY, Ye CY, Jin CL, Lu YF, Yu X, Yu XP, Huang JR, Xu KL, Ni Q, Yu CB, Zhu B, Li YT, Liu J, Zhao H, Zhang X, Yu L, Guo YZ, Su JW, Tao JJ, Lang GJ, Wu XX, Wu WR, Qv TT, Xiang DR, Yi P, Shi D, Chen Y, Ren Y, Qiu YQ, Li LJ, Sheng J, Yang Y (2020) Epidemiological clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. https://doi.org/10.1136/gutjnl-2020-320926CrossRefPubMed

18.

Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q (2020) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368:m1091. https://doi.org/10.1136/bmj.m1091CrossRefPubMedPubMedCentral

19.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. https://doi.org/10.1016/S0140-6736(20)30566-3CrossRefPubMedPubMedCentral

20.

Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, Xiong Y, Cheng Z, Gao S, Liang K, Luo M, Chen T, Song S, Ma Z, Chen X, Zheng R, Cao Q, Wang F, Zhang Y (2020) Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa270CrossRef

21.

Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD (2020) Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. https://doi.org/10.1111/all.14238CrossRefPubMed

22.

Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong Y, Huang X, Lv J, Luo Y, Shen L, Yang H, Huang G, Yang R (2020) Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol. https://doi.org/10.1002/jmv.25783CrossRefPubMedPubMedCentral

23.

Liu W, Tao ZW, Lei W, Ming-Li Y, Kui L, Ling Z, Shuang W, Yan D, Jing L, Liu HG, Ming Y, Yi H (2020) Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). https://doi.org/10.1097/CM9.0000000000000775CrossRefPubMedPubMedCentral

24.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5CrossRefPubMedPubMedCentral

25.

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z (2020) Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1017CrossRefPubMedPubMedCentral

26.

Zhang X, Cai H, Hu J, Lian J, Gu J, Zhang S, Ye C, Lu Y, Jin C, Yu G, Jia H, Zhang Y, Sheng J, Li L, Yang Y (2020) Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis. https://doi.org/10.1016/j.ijid.2020.03.040CrossRefPubMedPubMedCentral

27.

Statista. Population in China from 2008 to 2018, by gender. https://www.statista.com/statistics/251129/population-in-china-by-gender/. Accessed 9 Apr 2020

28.

Liu S, Zhang M, Yang L, Li Y, Wang L, Huang Z, Wang L, Chen Z, Zhou M (2017) Prevalence and patterns of tobacco smoking among Chinese adult men and women: findings of the 2010 national smoking survey. J Epidemiol Community Health 71(2):154–161. https://doi.org/10.1136/jech-2016-207805CrossRefPubMed

29.

Lippi G, Henry BM (2020) Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. https://doi.org/10.1016/j.ejim.2020.03.014CrossRefPubMedPubMedCentral

30.

Vardavas CI, Nikitara K (2020) COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis 20(18):20. https://doi.org/10.18332/tid/119324CrossRef

31.

Centers for Disease Control and Prevention (2020) Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. https://doi.org/10.15585/mmwr.mm6913e2CrossRef

32.

Dreher M, Kersten A, Bickenbach J, Balfanz P, Hartmann B, Cornelissen C, Daher A, Stöhr R, Kleines M, Lemmen SW, Brokmann JC, Müller T, Müller-Wieland D, Marx G, Marx N (2020) Charakteristik von 50 hospitalisierten COVID-19-Patienten mit und ohne ARDS. (The characteristics of 50 hospitalized COVID-19 patients with and without ARDS). Dtsch Arztebl Int 117:271–278. https://doi.org/10.3238/arztebl.2020.0271CrossRefPubMedPubMedCentral

33.

Mabley J, Gordon S, Pacher P (2011) Nicotine exerts an anti-inflammatory effect in a murine model of acute lung injury. Inflammation 34(4):231–237. https://doi.org/10.1007/s10753-010-9228-xCrossRefPubMed

34.

Li Q, Zhou XD, Kolosov VP, Perelman JM (2011) Nicotine reduces TNF-α expression through a α7 nAChR/MyD88/NF-ĸB pathway in HBE16 airway epithelial cells. Cell Physiol Biochem 27(5):605–612. https://doi.org/10.1159/000329982CrossRefPubMed

35.

Wittebole X, Hahm S, Coyle SM, Kumar A, Calvano SE, Lowry SF (2007) Nicotine exposure alters in vivo human responses to endotoxin. Clin Exp Immunol 147:28–34PubMedPubMedCentral

36.

Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421(6921):384–388CrossRefPubMed

37.

Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Wang H, Metz C, Miller EJ, Tracey KJ, Ulloa L (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10:1216–1221CrossRefPubMed

38.

van Westerloo DJ, Giebelen IA, Florquin S, Daalhuisen J, Bruno MJ, de Vos AF, Tracey KJ, van der Poll T (2005) The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis 191:2138–2148CrossRefPubMed

39.

Tracey KJ (2007) Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Investig 117(2):289–296CrossRefPubMedPubMedCentral

40.

Ulloa L (2005) The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov 4(8):673–684CrossRefPubMed

41.

de Jonge WJ, Ulloa L (2007) The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 151(7):915–929CrossRefPubMedPubMedCentral

42.

Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ (2003) The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol Med 9:125–134CrossRefPubMedPubMedCentral

43.

Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK (2020) Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. https://doi.org/10.23812/CONTI-ECrossRefPubMed

44.

Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (2020) The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 28:105954. https://doi.org/10.1016/j.ijantimicag.2020.105954CrossRef

45.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8(4):420–422. https://doi.org/10.1016/S2213-2600(20)30076-XEpub 2020 Feb 18CrossRefPubMedPubMedCentral

46.

Georgiev T (2020) Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. Rheumatol Int. https://doi.org/10.1007/s00296-020-04570-zCrossRefPubMedPubMedCentral

47.

Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. https://doi.org/10.1007/s00134-020-05991-xCrossRefPubMedPubMedCentral

48.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033–1034. https://doi.org/10.1016/S0140-6736(20),30628-0CrossRefPubMedPubMedCentral

49.

Slatter H. FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia. CancerNetwork. March 26, 2020. https://www.cancernetwork.com/news/fda-approves-phase-iii-clinical-trial-tocilizumab-covid-19-pneumonia. Accessed 4 April 2020

50.

Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, Richards D, Hussell T (2020) Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. https://doi.org/10.1016/S0140-6736(20)30858-8CrossRefPubMedPubMedCentral

51.

Imai Y, Kuba K, Penninger JM (2008) The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol 93(5):543–548. https://doi.org/10.1113/expphysiol.2007.040048CrossRefPubMedPubMedCentral

52.

Hung YH, Hsieh WY, Hsieh JS, Liu FC, Tsai CH, Lu LC, Huang CY, Wu CL, Lin CS (2016) Alternative roles of STAT3 and MAPK signaling pathways in the MMPs activation and progression of lung injury induced by cigarette smoke exposure in ACE2 knockout mice. Int J Biol Sci 12:454–465. https://doi.org/10.7150/ijbs.13379CrossRefPubMedPubMedCentral

53.

Cristiani L, Mancino E, Matera L, Nenna R, Pierangeli A, Scagnolari C, Midulla F (2020) Will children reveal their secret? The coronavirus dilemma. Eur Respir J. https://doi.org/10.1183/13993003.00749-2020CrossRefPubMedPubMedCentral

54.

Ciaglia E, Vecchione C, Puca AA (2020) COVID-19 infection and the predictive ACE2 soluble levels: the favourable protection of children and women. Front Pediatr. https://doi.org/10.3389/fped.2020.00206CrossRefPubMedPubMedCentral

55.

Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MA, Feyerabend C, Thomas GA, Sawe U (1994) Transdermal nicotine for active ulcerative colitis. N Engl J Med 330(12):811–815CrossRefPubMed

56.

Villafane G, Cesaro P, Rialland A, Baloul S, Azimi S, Bourdet C, Le Houezec J, Macquin-Mavier I, Maison P (2007) Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur J Neurol 14(12):1313–1316 (Epub 2007 Oct 17)CrossRefPubMed

57.

Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED (2012) Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 78(2):91–101. https://doi.org/10.1212/WNL.0b013e31823efcbbCrossRefPubMedPubMedCentral

58.

Simis K, Lei M, Lu AT, Sharma KC, Hale RL, Timmons R, Cassella J (2008) Nicotine aerosol generation from thermally reversible zinc halide complexes using the Staccato system. Drug Dev Ind Pharm 34(9):936–942. https://doi.org/10.1080/03639040802149061CrossRefPubMed

59.

RESPADD. Prendre en charge les fumeurs dans les lieux de santé. Un livret d’aide à la pratique pour les professionnels. https://www.respadd.org/wp-content/uploads/2019/09/Livret-Prise-en-charge-LSST-09-2019-BAT3.pdf. Accessed 18 April 2020

Titel: Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?
verfasst von: Konstantinos Farsalinos
Anastasia Barbouni
Raymond Niaura
Publikationsdatum: 09.05.2020
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Internal and Emergency Medicine / Ausgabe 5/2020
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-020-02355-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

So häufig greift rheumatoide Arthritis auf Organe über

Blutdrucksenkung könnte Uterusmyome verhindern

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Update Innere Medizin

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Flowchart for non-invasive ventilation support in COVID-19 patients from a northern Italy Emergency Department

Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol

Potential role of incretins in diabetes and COVID-19 infection: a hypothesis worth exploring

Triage decision-making at the time of COVID-19 infection: the Piacenza strategy

Bilateral lower limb weakness: a cerebrovascular consequence of covid-19 or a complication associated with it?

COVID-19 and elderly: beyond the respiratory drama

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

So häufig greift rheumatoide Arthritis auf Organe über

Blutdrucksenkung könnte Uterusmyome verhindern

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Update Innere Medizin